Rhenman & Partners Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.4M	Sell	34,465 -11,210	-25%	-$3.81M	1.41%	26
2025 Q4	$18.2M	Buy	45,675 +13,800	+43%	+$6.11M	1.7%	19
2025 Q3	$14.5M	Sell	31,875 -19,322	-38%	-$7.87M	1.61%	25
2025 Q2	$16.7M	Buy	51,197 +3,000	+6%	+$830K	2.11%	17
2025 Q1	$13M	Buy	48,197 +31,197	+184%	+$8.02M	1.5%	27
2024 Q4	$4M	Sell	17,000 -33,350	-66%	-$8.77M	0.41%	61
2024 Q3	$13.8M	Sell	50,350 -35,150	-41%	-$9.15M	1.12%	32
2024 Q2	$20.8M	Buy	85,500 +43,200	+102%	+$6.82M	1.99%	17
2024 Q1	$6.32M	Buy	42,300 +4,800	+13%	+$801K	0.6%	51
2023 Q4	$7.18M	Sell	37,500 -7,500	-17%	-$1.28M	0.72%	48
2023 Q3	$7.97M	Hold	45,000	–	–	0.86%	40
2023 Q2	$8.55M	Sell	45,000 -31,000	-41%	-$6.15M	0.9%	38
2023 Q1	$14.8M	Buy	76,000 +3,000	+4%	+$631K	1.63%	22
2022 Q4	$17.3M	Sell	73,000 -2,000	-3%	-$427K	1.81%	22
2022 Q3	$15.5M	Hold	75,000	–	–	1.63%	24
2022 Q2	$10.9M	Sell	75,000 -55,000	-42%	-$7.8M	1.24%	33
2022 Q1	$21.2M	Sell	130,000 -45,000	-26%	-$6.86M	2.09%	14
2021 Q4	$29.9M	Buy	175,000 +75,000	+75%	+$13.9M	1.99%	15
2021 Q3	$18.9M	Sell	100,000 -35,000	-26%	-$6.57M	1.33%	28
2021 Q2	$22.9M	Hold	135,000	–	–	1.55%	23
2021 Q1	$19.1M	Buy	135,000 +23,300	+21%	+$3.51M	1.33%	34
2020 Q4	$14.5M	Buy	111,700 +11,700	+12%	+$1.56M	1.18%	37
2020 Q3	$14.6M	Buy	100,000 +37,905	+61%	+$5.39M	1.29%	33
2020 Q2	$9.2M	Sell	62,095 -17,905	-22%	-$2.41M	0.99%	41
2020 Q1	$8.71M	Buy	80,000 +19,285	+32%	+$2.23M	1.22%	35
2019 Q4	$6.99M	Sell	60,715 -8,285	-12%	-$826K	0.77%	54
2019 Q3	$5.55M	Sell	69,000 -12,550	-15%	-$993K	0.7%	54
2019 Q2	$5.92M	Sell	81,550 -10,000	-11%	-$767K	0.65%	55
2019 Q1	$8.55M	Sell	91,550 -20,000	-18%	-$1.67M	1%	44
2018 Q4	$8.13M	Sell	111,550 -60,400	-35%	-$4.65M	0.93%	45
2018 Q3	$15M	Buy	171,950 +57,983	+51%	+$5.83M	1.51%	30
2018 Q2	$11.2M	Buy	113,967 +30,000	+36%	+$2.98M	1.15%	42
2018 Q1	$10M	Buy	83,967 +25,000	+42%	+$3.22M	1.23%	35
2017 Q4	$7.49M	Buy	58,967 +16,174	+38%	+$2.03M	1.01%	42
2017 Q3	$5.03M	Sell	42,793 -37,397	-47%	-$3.19M	0.64%	60
2017 Q2	$6.4M	Sell	80,190 -49,810	-38%	-$3.18M	0.92%	40
2017 Q1	$6.66M	Sell	130,000 -5,000	-4%	-$231K	1.06%	35
2016 Q4	$5.05M	Buy	135,000 +5,000	+4%	+$209K	0.97%	39
2016 Q3	$8.81M	Sell	130,000 -65,000	-33%	-$4.59M	1.4%	23
2016 Q2	$10.8M	Buy	195,000 +70,000	+56%	+$4.41M	1.92%	16
2016 Q1	$7.85M	Buy	125,000 +63,000	+102%	+$4.19M	1.56%	23
2015 Q4	$5.84M	Sell	62,000 -14,000	-18%	-$1.3M	0.88%	46
2015 Q3	$6.11M	Buy	76,000 +14,600	+24%	+$1.62M	0.97%	43
2015 Q2	$7.36M	Buy	61,400 +8,400	+16%	+$1M	0.88%	33
2015 Q1	$5.53M	Buy	53,000 +30,000	+130%	+$3.04M	0.93%	39
2014 Q4	$2.23M	Buy	23,000 +9,970	+77%	+$924K	0.65%	69
2014 Q3	$1.02M	Buy	+13,030	New	+$841K	0.3%	90

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rhenman & Partners Asset Management's ALNY Position: Q1 2026 in Review

Rhenman & Partners Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 25% in Q1 2026, selling an estimated $3.81M and leaving 34,465 shares worth $11.4M. The position accounts for 1.41% of the portfolio, ranked #26.

Rhenman & Partners Asset Management first reported a position in ALNY in Q3 2014 and has held it in 47 quarters since. The position peaked at $29.9M in Q4 2021. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Rhenman & Partners Asset Management held 34,465 shares of Alnylam Pharmaceuticals worth $11.4M as of Q1 2026.
Rhenman & Partners Asset Management sold 11,210 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $3.81M.
Alnylam Pharmaceuticals made up 1.41% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #26 holding.
Rhenman & Partners Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2014 and has held it in 47 quarters since.
Rhenman & Partners Asset Management's Alnylam Pharmaceuticals position peaked at $29.9M in Q4 2021.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.